Status:
COMPLETED
Combined Antioxidant Therapy Against Myocardial Reperfusion Injury. Phase I Study.
Lead Sponsor:
University of Chile
Collaborating Sponsors:
Fondo Nacional de Desarrollo Científico y Tecnológico, Chile
Conditions:
Acute Myocardial Infarction
Ischemia-reperfusion Injury
Eligibility:
All Genders
18-35 years
Phase:
PHASE1
Brief Summary
Background: Acute myocardial infarction (AMI) has remained a leading cause of mortality and disability worldwide. Although percutaneous coronary angioplasty (PCA) is the best treatment for these patie...
Detailed Description
In this single-blind trial, healthy subjects from 18-35 years old will be allocated to a placebo or an intravenous combined antioxidant therapy (CAT) following a fixed-dose scalation approach. Before ...
Eligibility Criteria
Inclusion
- Healthy subjects from 18 to 35 years old
- Not obese (BMI 19-29.9 kg/m2)
Exclusion
- Impaired renal function (creatinine \> 1.5 mg/dL)
- Liver impairment (liver enzymes more than 3 times over normal values)
- Glucose 6-phosphate dehydrogenase deficiency
- Any chronic disease
- Any acute disease in the last two weeks
- To be enrolled in another clinical study
Key Trial Info
Start Date :
August 9 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 22 2022
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT05215743
Start Date
August 9 2022
End Date
December 22 2022
Last Update
January 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Chile
Santiago, Chile